Skip to content
ClinCalc Pro
Menu
Intranasal corticosteroid

Triamcinolone Acetonide 55 micrograms/actuation Nasal Spray (Nasacort)

Brand names: Nasacort

Triamcinolone acetonide nasal spray (Nasacort) is an intranasal corticosteroid used to relieve and prevent the symptoms of allergic rhinitis, including nasal congestion, rhinorrhoea, sneezing and itch.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Triamcinolone acetonide is a potent topical glucocorticoid that, applied to the nasal mucosa, suppresses local inflammatory mediators and reduces the cellular inflammatory response underlying allergic rhinitis.

Prescribing in practice

  • Regular daily use is needed for full benefit, as effect builds over days rather than providing immediate relief.
  • Local effects such as nasal dryness, irritation, crusting and epistaxis can occur, and incorrect aiming at the septum increases the risk of bleeding and, rarely, perforation.
  • With prolonged or high-dose use, and particularly when combined with inhaled or other corticosteroids, the small potential for systemic effects should be considered.

Monitoring

Monitor symptom control and the nasal mucosa for irritation or bleeding; with long-term use in children consider periodic review of growth.

Counselling the patient

  • Use it every day for ongoing control, not just when symptoms are bad.
  • Aim the spray slightly away from the central wall of the nose, towards the outer side.
  • Tell your prescriber if you get persistent nosebleeds or crusting.

Evidence & guidelines

Intranasal corticosteroids are recommended by NICE as the most effective treatment class for moderate-to-severe and persistent allergic rhinitis.

Reference: ARIA 2020; BSACI Allergic Rhinitis Guidelines; Nasacort SPC; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.